Q2 Earnings Forecast for Xencor Issued By Leerink Partnrs

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Leerink Partnrs decreased their Q2 2025 EPS estimates for shares of Xencor in a research note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst J. Chang now expects that the biopharmaceutical company will post earnings per share of ($0.77) for the quarter, down from their previous estimate of ($0.66). The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for Xencor's Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.88) EPS and FY2026 earnings at ($3.24) EPS.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $32.73 million during the quarter, compared to analyst estimates of $23.44 million. During the same period in the prior year, the business posted ($1.11) EPS. The company's revenue for the quarter was up 104.6% compared to the same quarter last year.

A number of other analysts have also recently weighed in on XNCR. Wells Fargo & Company decreased their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Wedbush reaffirmed an "outperform" rating and issued a $31.00 target price on shares of Xencor in a report on Wednesday, April 30th. William Blair began coverage on Xencor in a research note on Monday, April 21st. They set an "outperform" rating on the stock. StockNews.com downgraded Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Finally, Barclays cut their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research report on Thursday, May 8th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.50.

Xencor Price Performance

Shares of XNCR stock traded down $0.10 on Monday, hitting $8.10. 82,184 shares of the company's stock were exchanged, compared to its average volume of 646,337. The stock has a market cap of $576.33 million, a P/E ratio of -2.53 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The company has a 50 day moving average of $10.29 and a 200 day moving average of $17.30. Xencor has a 12 month low of $7.16 and a 12 month high of $27.24.

Insiders Place Their Bets

In related news, EVP Nancy Valente sold 4,616 shares of the stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the transaction, the executive vice president now directly owns 49,169 shares of the company's stock, valued at $542,334.07. This represents a 8.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.76% of the company's stock.

Institutional Investors Weigh In On Xencor

Several hedge funds and other institutional investors have recently bought and sold shares of XNCR. Barclays PLC increased its holdings in shares of Xencor by 100.7% during the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after acquiring an additional 78,066 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Xencor by 2.9% in the third quarter. JPMorgan Chase & Co. now owns 130,354 shares of the biopharmaceutical company's stock worth $2,621,000 after purchasing an additional 3,635 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 508 shares during the last quarter. KBC Group NV boosted its position in shares of Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock valued at $90,000 after buying an additional 813 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Xencor by 24.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,839 shares of the biopharmaceutical company's stock valued at $341,000 after buying an additional 2,946 shares during the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.